Impact of PIPAC-Oxaliplatin on Recovery and Survival in Cancer Patients
Author Information
Author(s): Waheed Muhammad Talha MD, Ruel Nora MA, Dellinger Thanh H. MD, Raoof Mustafa MD
Primary Institution: City of Hope National Medical Center
Hypothesis
Does PIPAC-oxaliplatin improve survival and quality of life in patients with refractory colorectal and appendiceal carcinomatosis compared to standard therapy?
Conclusion
PIPAC patients experienced significantly better survival and quality of life compared to those receiving standard therapy.
Supporting Evidence
- PIPAC patients had significantly lower hospitalizations compared to standard therapy patients.
- PIPAC patients had a higher median number of good days at 6 months and 1 year.
- Overall survival for PIPAC patients was significantly longer than for those receiving standard therapy.
Takeaway
This study shows that a special treatment called PIPAC can help cancer patients live longer and feel better than regular treatments.
Methodology
The study compared PIPAC treatment outcomes with a matched cohort receiving standard therapy, focusing on survival and quality of life metrics.
Potential Biases
Selection bias was mitigated by careful cohort selection.
Limitations
The study is retrospective, which limits the ability to draw definitive conclusions about the efficacy of PIPAC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website